Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Colorectal Cancer
- Interventions
- Drug: HR070803 plus oxaliplatin, 5-FU/LV, bevacizumabDrug: HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 606
- Registration Number
- NCT05945901
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdog, China
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1
Recruiting
- Conditions
- Advanced Prostate Cancer
- Interventions
- Drug: HRS-5041
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05942001
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, Shanghai, China
A Study to Evaluate the Effect of Itraconazole on Pharmacokinetics (PK) of SHR8554 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: SHR8554；Itraconazole
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT05928988
- Locations
- 🇨🇳
Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China
A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05913336
- Locations
- 🇨🇳
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
A Study of SHR-A1811 in Subjects With Gynaecologic Oncology
Phase 2
Recruiting
- Conditions
- Gynaecological Malignancies
- Interventions
- Drug: SHR- A1811
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 225
- Registration Number
- NCT05896020
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
To Compare the Pharmacokinetics and Pharmacodynamics of HR20014, INS068 and INS062 After Single Subcutaneous Injection in Healthy Subjects
Phase 1
Completed
- Conditions
- Diabetes
- Interventions
- Drug: INS062 injection、INS068 injection、HR20014 injection
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05887895
- Locations
- 🇨🇳
The second affiliated hospital of Anhui Medical University, Hefei, Anhui, China
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Phase 3
Recruiting
- Conditions
- Advanced Gastroenteropancreatic Neuroendocrine Tumor
- Interventions
- Drug: Lutetium (177Lu) Oxodotreotide Injection；long-acting OctreotideDrug: long-acting Octreotide.
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT05884255
- Locations
- 🇨🇳
Tianjin University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets
Phase 1
Completed
- Conditions
- Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction
- Interventions
- Drug: SHR7280 tabletsDrug: SHR7280 dry suspension
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05868057
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
Phase 3
Not yet recruiting
- Conditions
- Chemotherapy-Induced Thrombocytopenia
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 192
- Registration Number
- NCT05864014
To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability
Phase 1
Completed
- Conditions
- Graft-versus-host Disease
- Interventions
- Drug: SHR0302
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05856058
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath